May 4, 2023 02:56 PM EDT
R&D
Pharma

With Eylea in de­cline, Re­gen­eron awaits FDA ap­proval for high­er dose of block­buster

Paul Schloesser

Associate Editor

Re­gen­eron is bank­ing on get­ting a high­er dose of afliber­cept, the Bay­er-part­nered wet AMD drug al­so known as Eylea, to the US mar­ket as soon …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times